Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
I am a medical professional, but I have been studying investing for many years so that I can control my own portfolio. DGI seems to be the best way for me to invest for my retirement while being able to sleep at night.
I have also been successfully trading cash secured puts for extra income. I share my experience on my websites, Tradingcsps.com and my blog Tradingputs.com.
It's been quite a journey the past five years as I've learned about stocks, technical analysis, swing trading, dividend growth investing, and now options. For 17 years, I home educated our children and tutored, while my husband supported the family. Once I worked myself out of that job, I had to decide what I should be when I grow up. Without a useful degree, my income is minimal, but I really enjoy my part-time jobs. I have used my jobs as a learning tool more than an income tool and they have been very profitable. I focus the rest of my time making my husband's income the most useful it can be, and managing our home. I enjoy playing with bookkeeping, finance, investments, taxes, and strive to be the best steward of all the resources (time, energy, health, family, money, stuff) we have. The only purpose of my investing was to be able to afford to retire at a normal, reasonable age and hopefully to live off the dividends from those investments without needing to spend down the principal. As health concerns are forcing us to consider earlier retirement, the portfolio income may be needed at anytime. This does not worry me, it just changes the trajectory of the portfolio. I am very thankful for the gentle start into investing and am excited by what might happen in the future. I’m so glad this website was recommended to me and I genuinely appreciate the contributors and their comments here and the growth that has happened through participation on the forum. In case you're wondering about 'inzkeeper', I formerly managed an inn and the email moniker has stuck with me over the years.
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: email@example.com (mailto:firstname.lastname@example.org)
James A. Shell is currently working as an ISO9001 Quality Systems Consultant and a technical consultant to various other industries,
A veteran of 3 decades in the petrochemical supply chain, I have worked with customers in 19 countries on four continents on formulation development, business development, recycling, logistics, and process improvement projects.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
B.A. in economics and MBA from top 10 business school. I have over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange (www.newyorkshockexchange.com), a youth mentorship program that teaches investment management skills and competitive basketball skills.
Richard Evans spent 26 years in the military, Business and Management as well as marketing within the retail, transportation, education and health care fields. He now lives in Las Vegas.
He writes extensively, having several hundred articles published on financial and travel topics as well as one guide book, with the help of two part time researchers.
His personal investment philosophy is "complicated."
He combines a selection of value/growth/dividend companies, in his best Warren Buffet imitation, along with a significant element to take advantage of arbitrage and other short term opportunities in the market.
Richard Evans concentrates on Energy companies, dividend opportunities, special opportunities and arbitrage, and because he does live in Las Vegas he keeps a weather eye on the Gaming Industry.
At Valuentum, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Valuentum therefore analyzes each stock across a wide spectrum of philosophies, from deep value through momentum investing. We think companies that are attractive from a number of investment perspectives--whether it be growth, value, momentum, etc.--have the greatest probability of capital appreciation and relative outperformance. The more investors that are interested in the stock for reasons based on their respective investment mandates, the more likely it will move higher.
Brian Nelson is the President of Equity Research at Valuentum Securities, an investment research firm serving individual and institutional investors, as well as financial advisors. Before founding Valuentum, Mr. Nelson worked as a director at Morningstar, where he was responsible for training and methodology development within the firm's equity and credit research department. Prior to that position, he served as a senior industrials securities analyst, covering aerospace, airlines, construction and environmental services companies. Before joining Morningstar in February 2006, Mr. Nelson worked for a small capitalization fund covering a variety of sectors for an aggressive growth investment management firm in Chicago. He holds a Bachelor's degree in finance and a minor in mathematics, magna cum laude, from Benedictine University. Mr. Nelson has an MBA from the University of Chicago Booth School of Business and also holds the Chartered Financial Analyst (CFA) designation.
Get to Know Brian:
Brian led the charge in developing Morningstar's issuer credit ratings, developing and rolling-out one of the firm's proprietary credit metrics, the Cash Flow Cushion. http://select.morningstar.com/welcome/credit/pdfs/Morningstar_CashFlowCushion.pdf
Brian is frequently quoted in the media and has been a frequent guest on Nightly Business Report, Bloomberg TV, and the Money Show.
Mr. Nelson is very experienced in valuing equities, developing Morningstar's discounted cash-flow model used to derive the fair value estimates for the company's entire equity coverage universe.
Brian worked on a small cap fund and a micro cap fund that were ranked within the top 10th percentile and top 1st percentile within the Small Cap Lipper Growth Universe, respectively, in 2005.
Mr. Nelson is also a contributor to Seeking Alpha and an opinion leader in the Industrial Goods space.
You can reach Brian at email@example.com.
Please read our Disclaimer that applies to all articles published on Seeking Alpha: http://www.valuentum.com/categories/20110613
Follow us on Twitter: @Valuentum
Mr. Hui has been involved in the equity markets since 1980, both on the buy side and the sell side. He is a CFA Charterholder, and has presented numerous papers to quantitative discussion groups (Sample topics include: How Global are Resource Sectors).
Kapitall is the online finance platform for the next generation, where investing is as easy as drag, drop and trade. With an intuitive and playful user experience, Kapitall offers tools that make it easy to build virtual and real brokerage portfolios, share ideas and research stocks and funds.
Hao Jin is a Chartered Financial Analyst (CFA) Charterholder, Certified Management Accountant (CMA), and currently works as an IT professional for a media brokerage firm in Wall Street area, doing data mining, data warehouse and analytic reports. He graduated from SUNY Stony Brook’s Harriman School for Management and Policy in 1993.
Marco is a trader of stocks, options, currencies, and futures. He has been fascinated with the financial markets ever since he bought his first stock at 11 years old. Marco entered the business world at the age of 13, with the creation of an extremely successful retail website (GoldenAgeCheese.com), that of which he still has a major role in today. Marco writes about stocks and options whenever he gets the chance. He's dedicated to educate his readers to the best of his ability about the financial markets, particularly about buying/selling options and different strategies. 2008 was one of the most profitable years trading stocks and options for Marco. He trades based on technicals and fundamentals, so you may find many of his posts valuable.
Greentech Media (GTM) produces industry-leading news, research, and conferences in the business-to-business greentech market. Our coverage areas include solar, smart grid, energy efficiency, wind, and other non-incumbent energy markets. GTM Research, the research arm of the company, produces competitive intelligence reports and data subscriptions.
Read additional coverage on the renewable energy market on our website: www.greentechmedia.com, and gain additional insight by signing up for our research services at www.gtmresearch.com.
You can also follow us on twitter: @greentechmedia, or like us on Facebook: facebook.com/greentechmedia.
Data Explorers (www.dataexplorers.com), based in New York and London, is the world's most complete resource for data, analysis and insight into short-selling. The company's proprietary data gives an unrivalled, comprehensive view on share lending and short-selling activity. With data sourced directly from securities lending desks of over 100 of the top lending firms and representing most of the global securities lending market, Data Explorers has built a reputation with leading financial institutions as the source for short intelligence that informs their decision-making and their coverage of market sectors and companies.
For more information on Data Explorers or the short position on any globally listed stock, please contact Erika Alter on firstname.lastname@example.org or +1 212 710 2210.
UK: +44 (0)207 264 7600 | US: +1 212 710 2210 | email@example.com |
75 Rockefeller Plaza, New York, NY, 10019, USA
2 Seething Lane, London, EC3N4AT, UK